Skip to main content
. 2022 Sep 28;36(6):749–760. doi: 10.1007/s40259-022-00552-8

Fig. 2.

Fig. 2

Kaplan–Meier plots depicting a progression-free survival as assessed by central review, and b overall survival (intent-to-treat population). CI confidence interval, EU-bevacizumab European Union-approved reference bevacizumab, HR hazard ratio